N/A
Manufactured by Covis Pharma US, Inc
27,417 FDA adverse event reports analyzed
Last updated: 2026-04-15
ACLIDINIUM BROMIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Covis Pharma US, Inc. The most commonly reported adverse reactions for ACLIDINIUM BROMIDE include DYSPNOEA, DEVICE MALFUNCTION, DRUG DOSE OMISSION, ASTHMA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for ACLIDINIUM BROMIDE.
Out of 6,311 classified reports for ACLIDINIUM BROMIDE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 27,417 FDA FAERS reports that mention ACLIDINIUM BROMIDE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DYSPNOEA, DEVICE MALFUNCTION, DRUG DOSE OMISSION, ASTHMA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, INTENTIONAL PRODUCT MISUSE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Covis Pharma US, Inc in connection with ACLIDINIUM BROMIDE. Always verify the specific product and NDC with your pharmacist.